Atea Pharmaceuticals, Inc. — Director's Dealing 2026

Feb 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2026-01-31

Reporting Person: Vavricka John (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-31	Common Stock	M	42083	—	Acquired	94164	Direct
2026-01-31	Common Stock	F	11570	$4.24	Disposed	82594	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-31	Restricted Stock Units	$	M	33333	Disposed		Common Stock (33333)	Direct
2026-01-31	Restricted Stock Units	$	M	8750	Disposed		Common Stock (8750)	Direct
2026-01-31	Stock Option (Right to Buy)	$4.24	A	119520	Acquired	2036-01-30	Common Stock (119520)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	82508	Indirect

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

F4: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.